Shëndeti

Pfizer is making a new vaccine, specifically to combat the Covid Delta variant

Pfizer is making a new vaccine, specifically to combat the Covid Delta variant

Pfizer & BioNTech have announced that they are working to develop a new version of the anti-Covid vaccine, a variant that aims to protect against Delta. The company is ready to launch clinical trials of the vaccine in August.

What is Delta?

Delta is a highly contagious variant that has spread to nearly 100 countries around the world. It is also present in neighboring countries and the region, but in Albania the first cases have not been confirmed yet. Delta, the dual-mutant Indian variant of Sars Cov 2 is much more contagious. Researchers believe that 5 to 10 seconds is enough to get infected if you stay close to someone who is positive.

The Delta variant is believed to be about 60% more sticky than the Alpha, the British version. It is not yet clear if it is more dangerous, but the faster spread makes it affect more people and consequently have more paved.

What about the third dose?

Pfizer and BioNTech also reported promising results from studies they did on the third dose of the vaccine. An enhancer given six months after the second dose increases the potency of antibodies against the base virus and secondary variants. Efficiency increases almost 10-fold.

Efikasiteti i vaksinës mund të bjerë gjashtë muaj pas imunizimit. Plus mutacionet që dalin herë pas herë, ndaj lind nevoja i një doze të tretë.

Si është përgatitur vaksina e re?

Vaksina e re do të synojë tërësinë e proteinave spike, në krahasim me një pjesë, që janë përfshirë në variantin e deritanishëm të dozave.

What about those vaccinated so far with two normal doses of Pfizer BioNTech how protected are they by Delta?

The work team analyzed blood samples from 59 people after receiving the first and second doses of vaccines. Blood samples from only 10% of people immunized with a single dose of AstraZeneca or Pfizer-BioNTech vaccines were able to neutralize the Delta and Beta variants in laboratory experiments.

'A single dose of Pfizer or AstraZeneca was either weak or not at all effective against the Beta and Delta variants,' the researchers concluded. But a second dose increased the efficiency to 95%.

* The New York Times article was adapted in Albanian by Tiranapost.al